DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Is natalizumab a breakthrough in the treatment of multiple sclerosis?

Author(s): Doggrell SA

Affiliation(s): School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia. s_doggrell@yahoo.com

Publication date & source: 2003-06, Expert Opin Pharmacother., 4(6):999-1001.

Publication type: Clinical Trial; Comparative Study; Multicenter Study; Randomized Controlled Trial

In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in the Expanded Disability Status Scale scores in any of the groups. Natalizumab was well-tolerated. Thus, the initial results with natalizumab treatment over 6 months in multiple sclerosis are encouraging.

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017